US20080200493A1 - Use of Oxycodone for Treating Visceral Pain - Google Patents

Use of Oxycodone for Treating Visceral Pain Download PDF

Info

Publication number
US20080200493A1
US20080200493A1 US11/814,020 US81402006A US2008200493A1 US 20080200493 A1 US20080200493 A1 US 20080200493A1 US 81402006 A US81402006 A US 81402006A US 2008200493 A1 US2008200493 A1 US 2008200493A1
Authority
US
United States
Prior art keywords
oxycodone
pain
salt
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/814,020
Other languages
English (en)
Inventor
Asbjorn Mohr Drewes
Lars Arendt Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Purdue Pharma LP
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080200493(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Priority to US11/814,020 priority Critical patent/US20080200493A1/en
Assigned to PURDUE PHARMA L.P. reassignment PURDUE PHARMA L.P. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DREWES, ASBJORN MOHR, NIELSEN, LARS ARENDT
Publication of US20080200493A1 publication Critical patent/US20080200493A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Definitions

  • the present invention refers to the treatment of visceral pain.
  • analgesic medications which are suitable for effectively treating visceral pain and especially acute visceral pain.
  • Deep pain from the internal organs is a common cause of visits to doctors and long-term sick leave in the western world.
  • the causes for visceral pain can be sought in both organic and functional conditions, but what is common to these is that there is complex activation of the nervous system.
  • the visceral pain persists despite the original cause having been wholly or partially eliminated.
  • morphine is currently used for the treatment of moderate to severe visceral pain.
  • analgesic medications able to provide high efficacy pain relief while reducing the possibility of undesirable effects. Accordingly, it is most desirable to have analgesic medications which provide high efficacy pain relief at low dosages in order to avoid or at least reduce undesirable effects and especially side-effects observed at higher dosages or for certain specific analgesics.
  • opioids are prescribed with increasing frequency, knowledge of their effect on visceral pain is limited.
  • morphine may also cause a number of undesirable effects, including, for example, respiratory depression, nausea, vomiting, dizziness, mental clouding, dysphoria, pruritus, constipation, increased biliary tract pressure, urinary retention and hypotension.
  • Visceral pain differs from pain in the skin in many ways and is often more difficult to treat.
  • different types of pain associated with disease of the viscera are suggested. These types comprise true or localized visceral pain, referred visceral pain, localized parietal pain, and referred parietal pain.
  • the present invention especially refers to the treatment of true or localized visceral pain.
  • True visceral pain often occurs early in the disease and is characterized by a vague, diffuse, dull, aching pain, which is localized but can have a tendency to radiate. It can be accompanied by a feeling of malaise, and, when severe, it induces strong autonomic phenomena such as sweating, vasomotor responses, bradycardia, nausea and vomiting, and sometimes an alarm reaction. It is usually felt in the midline and deep in the body.
  • visceral pain there are a variety of conditions in which visceral pain may exist. For example, pancreatitis pain, labor pain, pain from abdominal surgery associated with ileus, pain in irritable bowel syndrome, abdominal pain in nonulcer dyspepsia, or in dysmenorrhea. Likewise, liver pain, kidney pain, epigastric pain, pleural pain, and painful biliary colic, appendicitis pain may all be considered to be visceral pain. Substernal pain or pressure from early myocardial infarction is also visceral. Diseases of the stomach, dudenum or colon can cause visceral pain. And there are more.
  • the present invention it has been found that it is possible to effectively treat moderate to severe visceral pain by administering analgesic medications comprising the opioid oxycodone or pharmaceutically acceptable salts thereof. Moreover, it has been found that visceral pain and especially acute (i.e. non-chronic) visceral pain can be effectively treated by administering oxycodone at a dosage which is lower than the corresponding dosage of other opioids like morphine. Accordingly, the present invention inter alia refers to a method of effectively treating moderate to severe visceral pain by administering oxycodone at relatively low dosages.
  • treating visceral pain with a specific dosage of oxycodone is more effective than treating the same visceral pain with a higher corresponding dosage of morphine, whereas almost the same effect is observed if cutaneous or muscular pain is treated by administering corresponding dosages of oxycodone or morphine.
  • visceral pain and especially acute moderate to severe visceral pain can be effectively treated by administering oxycodone at relatively low dosages, whereas the “corresponding dosage” of morphine would be less effective in treating the same visceral pain.
  • the “corresponding dosage” of morphine does not mean the same quantitative amount of morphine, but refers to the usual equipotent amount of morphine, i.e. to the amount of morphine which usually provides a similar pain relief to the patient.
  • the usual equipotent weight ratio of morphine to oxycodone for oral administration is about 2:1 (the corresponding molar ratio is about 1.8:1).
  • a method of selectively treating moderate to severe visceral pain in a patient comprising administering oxycodone in an effective amount to provide analgesia in the patient in need thereof.
  • the present invention for the first time allows for the selective treatment of moderate to severe visceral pain, since it was not known prior to the present invention that this specific pain can be effectively treated by administering oxycodone at low dosages, whereas other opioids (like morphine) at dosages, which would have been considered equipotent by the skilled person, are less effective.
  • a method of treating moderate to severe visceral pain in a patient already being treated with morphine or a salt thereof comprising:
  • a method of treating moderate to severe visceral pain in a patient already being treated with hydromorphone, oxymorphone, codeine, hydrocodone or salts thereof comprising:
  • An embodiment of the present invention also allows the treatment of acute visceral pain by administering oxycodone at a dosage which is sufficiently low in order to reduce or avoid undesired side effects. This means, that therapeutic levels can be achieved without or with fewer concurrent side effects, such as nausea, vomiting, constipation and drowsiness, which may be associated with high blood levels of oxycodone.
  • visceral pain can be effectively treated by administering low dosages of oxycodone allows for the use of immediate release formulations and sustained release formulations. It may be preferred according to the present invention to treat visceral pain and especially acute visceral pain by administering oxycodone-containing once-a-day, twice-a-day, three-times-a-day, or four-times-a-day dosage forms. According to the present invention it may be especially preferred to use oxycodone-containing sustained release formulations, wherein the dosage does not exceed 40 mg oxycodone, preferably does not exceed 30 mg oxycodone and even more preferably does not exceed 10 mg oxycodone.
  • oxycodone-containing sustained release formulations and preferably once-a-day, twice-a-day, three-times-a-day, or four-times-a-day dosage forms comprising about 10 mg, about 9 mg, about 8 mg, about 7 mg, about 6 mg or about 5 mg oxycodone. It is also preferred in certain embodiments to use single-entity oxycodone or salts thereof, e.g., oxycodone or salts thereof without APAPs or other active agents.
  • the present invention relates to the treatment of visceral pain including pancreatitis pain, labor pain, pain from abdominal surgery associated with ileus, pain in irritable bowel syndrome, abdominal pain in nonulcer dyspepsia, or in dysmenorrhea, liver pain, kidney pain, epigastric pain, pleural pain, and painful biliary colic and appendicitis pain by administering analgesic medications comprising the oxycodone alone or in combination with other active agents and especially other analgesics.
  • the present invention refers to the treatment of visceral pain resulting from diseases of the stomach, dudenum or colon, from Crohn's disease, pain of the gall bladder, severe menstruational pain, and certain post operative pain conditions.
  • the present invention also relates to the treatment of moderate, moderately severe, and/or severe visceral pain.
  • the dosage form to be used for treating visceral pain preferably is an oral dosage form like a tablet or capsule, but could also be a suppository or any other solid or liquid dosage form which can be administered orally, via implant, parenterally, sublingually or rectally.
  • the formulation in accordance with the present invention is an oral tablet, capsule, or in any other suitable oral unit dosage form.
  • visceral pain can be treated by administering oxycodone or a pharmaceutically acceptable salt thereof.
  • pharmaceutically acceptable salt includes, but is not limited to, metal salts such as sodium salt, potassium salt, cesium salt and the like; alkaline earth metals such as calcium salt, magnesium salt and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N′-dibenzylethylenediamine salt and the like; inorganic acid salts such as hydrochloride, hydrobromide, sulfate, phosphate and the like; organic acid salts such as formate, acetate, trifluoroacetate, maleate, fumarate, tartrate and the like; sulfonates such as methanesulfonate, benzenesulfonate, p-toluenesulfonate, and the like
  • the Oxycodone-containing formulations which are suitable for treating visceral pain according to the present invention can be immediate release formulations or sustained release formulations. It may be preferred to use sustained release formulations for treating visceral pain and it may be especially advantageous to administer once-a-day, twice-a-day, three-times-a-day, or four-times-a-day dosage forms comprising oxycodone.
  • such oral dosage form includes a sustained-release material which is incorporated into a matrix along with the oxycodone or pharmaceutically acceptable salt thereof to provide for the sustained release of the oxycodone.
  • the sustained-release material may be hydrophobic or hydrophilic as desired.
  • the oral dosage form may be prepared as granules, spheroids, matrix multiparticulates, etc. which comprise oxycodone or a pharmaceutically acceptable salt thereof in a sustained release matrix, which may be compressed into a tablet or encapsulated.
  • the oral dosage form may optionally include other pharmaceutically acceptable ingredients (e.g., diluents, binders, colorants, lubricants, etc.).
  • hydrophilic and/or hydrophobic materials such as gums, cellulose ethers, acrylic resins, protein derived materials, waxes, shellac, and oils such as hydrogenated castor oil and hydrogenated vegetable oil.
  • any pharmaceutically acceptable hydrophobic or hydrophilic sustained-release material which is capable of imparting sustained-release of the oxycodone or pharmaceutically acceptable salt thereof may be used in accordance with the present invention.
  • Preferred sustained-release polymers include alkylcelluloses such as ethylcellulose, acrylic and methacrylic acid polymers and copolymers; and cellulose ethers, especially hydroxyalkylcelluloses (especially hydroxypropylmethylcellulose) and carboxyalkylcelluloses.
  • Preferred acrylic and methacrylic acid polymers and copolymers include methyl methacrylate, methyl methacrylate copolymers, ethoxyethyl methacrylates, ethyl acrylate, trimethyl ammonioethyl methacrylate, cyanoethyl methacrylate, aminoalkyl methacrylate copolymer, poly (acrylic acid), poly (methacrylic acid), methacrylic acid alkylamine copolymer, poly (methyl methacrylate), poly (methacrylic acid) (anhydride), polymethacrylate, polyacrylamide, poly (methacrylic acid anhydride), and glycidyl methacrylate copolymers.
  • Oxycodone-containing formulations which may be used for treating visceral pain according to the present invention, for example, are described in WO 02/087512 and EP 0 576 643, both incorporated herein by reference.
  • EP 0 576 643 refers to a solid, controlled release, oral dosage form, the dosage form comprising a therapeutically effective amount of oxycodone or a salt thereof in a matrix.
  • the oral dosage forms described in EP 0 576 643 may be especially suitable for the present invention.
  • the dosage forms according to EP 0 576 643 include “twice-a-day” formulations.
  • the oral dosage form may be presented as, for example, granules, spheroids or pellets in a capsule or in any other suitable solid form.
  • the oral dosage form contains between 1 and 50 mg, preferably between 1 and 15 mg, more preferably between 5 and 10 mg and especially about 5 mg of oxycodone hydrochloride.
  • the dosage form may contain the same or molar equivalent amounts of other oxycodone salts or of the oxycodone base.
  • the matrix of the dosage form to be used for treating visceral pain according to the present invention may preferably be a controlled release matrix, although also normal release matrices having a coating that controls the release of the drug may be used.
  • Suitable materials for inclusion in a controlled release matrix comprise
  • Hydrophilic polymers such as gums, cellulose ethers, acrylic resins and protein derived materials. Of these polymers, the cellulose ethers, especially hydroxyalkylcelluloses and carboxyalkylcelluloses, are preferred.
  • the dosage form may contain between 1% and 80% (by weight) of at least one hydrophilic or hydrophobic polymer.
  • the dosage form may contain up to 60% (by weight) of at least one digestible, long chain hydrocarbon.
  • the dosage form may contain up to 60% (by weight) of at least one polyalkylene glycol.
  • One particular suitable matrix comprises at least one water soluble hydroxyalkyl cellulose, at least one C12-C36, preferably C14-C22, aliphatic alcohol and, optionally, at least one polyalkylene glycol.
  • the at least one hydroxyalkyl cellulose may preferably be a hydroxy (C1 to C6) alkyl cellulose, such as hydroxypropylcellulose, hydroxypropylmethylcellulose and, especially, hydroxyethyl cellulose.
  • the amount of the at least one hydroxyalkyl cellulose in the oral dosage form will be determined, inter alia, by the precise rate of oxycodone release required.
  • the oral dosage form contains between 5% and 25%, especially between 6.25% and 15%. (by wt) of the at least one hydroxyalkyl cellulose.
  • the at least one aliphatic alcohol may be, for example, lauryl alcohol, myristyl alcohol or stearyl alcohol. In particularly preferred embodiments, however, the at least one aliphatic alcohol is cetyl alcohol or cetostearyl alcohol.
  • the amount of the at least one aliphatic alcohol in an oral dosage form will be determined by the precise rate of oxycodone release required.
  • the controlled release composition may comprise from about 5 to about 25% acrylic resin and from about 8 to about 40% by weight aliphatic alcohol by weight of the total dosage form.
  • a particularly preferred acrylic resin comprises Eudragit® RS 30D commercially available from Rohm Pharma.
  • a controlled release matrix may also contain suitable quantities of other materials, e.g. diluents, lubricants, binders, granulating aids, colorants, flavorants and glidants that are conventional in the pharmaceutical art.
  • the dosage form to be used for treating visceral pain may comprise a normal release matrix having a coat that controls the release of the drug.
  • the dosage form may comprise film coated spheroids containing active ingredient and a non-water soluble spheronising agent.
  • spheroid is known in the pharmaceutical art and means a spherical granule having a diameter of between 0.5 mm and 2.5 mm especially between 0.5 mm and 2 mm. Details with respect to film coated spheroids and the manufacture of the above-mentioned dosage forms are also described in EP 0 576 643, incorporated herein by reference.
  • Controlled release oxycodone-containing formulations which may be especially suitable for treating visceral pain according to the present invention may comprise oxycodone hydrochloride, lactose (spray dried), Povidone, Eudragit® RS 30 D (solids), Triaceting, stearyl alcohol, talc and magnesium stearate.
  • sustained release formulations containing oxycodone and being suitable for treating visceral pain according to the present invention are described in WO 02/087512, incorporated herein by reference.
  • the dosage form after administration to patients may provide a mean T max of oxycodone in-vivo which occurs at about 2 to about 17 hours (e.g., about 2 to about 8 hours) after administration at steady state of the dosage form.
  • mean for purposes of the present invention, when used to define a pharmacokinetic value (e.g., T max ) represents the arithmetic mean value measured across a patient population.
  • the mean T max of oxycodone in-vivo may occur at about 6.5 hours to about 17 hours, at about 8 to about 16 hours, at about 10 to about 16 hours, or at about 12 to about 16 hours after administration at steady state of the dosage form.
  • steady state means that the amount of the drug reaching the system is approximately the same as the amount of the drug leaving the system.
  • the patient's body eliminates the drug at approximately the same rate that the drug becomes available to the patient's system through absorption into the blood stream.
  • the sustained release oral dosage form which may be used for treating visceral pain according to the present invention comprises a matrix which includes a sustained release material and oxycodone or a pharmaceutically acceptable salt thereof.
  • the matrix is compressed into a tablet and may be optionally overcoated with a coating that in addition to the sustained release material of the matrix may control the release of the oxycodone or pharmaceutically acceptable salt thereof from the formulation, such that blood levels of active ingredient are maintained within the therapeutic range over an extended period of time.
  • the matrix may be encapsulated.
  • the sustained release oral dosage form to be used according to the present invention can be an osmotic dosage form which comprises a single layer or bilayer core comprising oxycodone or a pharmaceutically acceptable salt thereof; an expandable polymer; a semipermeable membrane surrounding the core; and a passageway disposed in the semipermeable membrane for sustained release of the oxycodone or pharmaceutically acceptable salt thereof, such that blood levels of active ingredient are maintained within the therapeutic range over an extended period of time when administered to patients.
  • the sustained release oral dosage form to be used according to the present invention comprises a substantially homogenous core comprising oxycodone or a pharmaceutically acceptable salt thereof and an expandable polymer; a semipermeable membrane surrounding the core; and a passageway disposed in the semipermeable membrane for sustained release of the oxycodone or pharmaceutically acceptable salt thereof, such that blood levels of active ingredient are maintained within the therapeutic range over an extended period of time when administered to a patients.
  • EP 1 449 531 Another sustained release oral analgesic dosage form which may be suitable for the use according to the present invention is described in EP 1 449 531, incorporated herein by reference.
  • Said dosage form comprises a combination of a pharmaceutical extrudate in the form of multiparticulates including 5 mg to 400 mg oxycodone or a salt thereof dispersed in a matrix.
  • EP 1 449 531 is also related in part to a new melt-extruded oral sustained-release dosage forms which comprise a pharmaceutically acceptable hydrophobic material, a retardant selected from waxes, fatty alcohols, and fatty acids, and a drug.
  • the extrudate can be divided into unit doses of the opioid analgesic.
  • the unit doses of multiparticulates may then be incorporated into a solid pharmaceutical dosage formulation, e.g. via compression or shaping into tablets, by placing a requisite amount inside a gelatin capsule, or by forming the extruded product into the form of a suppository.
  • EP 0 548 448 refers to a stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated substrate at a temperature and relative humidity elevated to a suitable level above ambient conditions until the coated dosage form attains a stabilized dissolution profile substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.
  • EP 0 531 611 refers to a controlled release dosage form having a matrix of sodium alginate and a calcium salt.
  • the matrix is combined with a therapeutically active agent and a suitable suppository base.
  • the matrix further includes a higher aliphatic alcohol.
  • EP 0 553 392, EP 0 630 646 and EP 0 636 366 refer to controlled release dosage forms having certain coatings.
  • EP 0 647 448 and EP 0 698 389 also refer to orally administrable opioid formulations providing controlled or sustained release of the active agent.
  • oxycodone-containing oral preparations which may be used for treating visceral pain according to the present invention.
  • These commercially available oxycodone-containing preparations include Oxynorm® (immediate release preparation) and OxyContin®.
  • OxyContin is a controlled release analgesic, which is commercially available from Purdue Pharma L.P.
  • OxyContin® is available in 10 mg, 20 mg, 40 mg, and 80 mg dosage strengths.
  • OxyContin is also commercially available in the U.K by Napp Pharmaceuticals in a 5 mg dosage strength. According to the present invention low dosage preparations may be preferred. Dosage forms having an OxyContin®-like matrix and comprising about 5 mg of oxycodone hydrochloride may be especially preferred
  • a dosage form which comprises a combination of opioid agonist and opioid antagonist in order to reduce or prevent the abuse potential.
  • Suitable dosage forms comprising combinations of opioid agonist and opioid antagonist are described, for example, in WO 99/32119, WO 99/32120, WO 01/58447, WO 03/013479 and WO 03/013476.
  • visceral pain is defined for purposes of the present invention as referring to pain within the viscera of the human body and especially to pain from the internal organs.
  • acute visceral pain is defined for purposes of the present invention as referring to visceral pain which is not chronic.
  • selective treating is defined for purposes of the present invention as referring to the selective use of oxycodone for effectively treating a specific pain, namely acute visceral pain.
  • the treatment of visceral pain with e.g. morphine would also lead to some analgesic effect, but would not be considered “selective” since such analgesic effect would be significantly lower in comparison to oxycodone and would also be observed for other pain. In other words, no selective effect would be observed for the treatment of visceral pain with morphine.
  • the present invention includes the following aspects:
  • a method of effectively treating visceral pain comprises administering oxycodone at a dosage which is sufficiently low in order to reduce or avoid undesired side effects.
  • a method of effectively treating visceral pain comprises administering a oxycodone-containing dosage form, wherein the dosage form provides immediate release or sustained release of the oxycodone.
  • a method of effectively treating visceral pain comprises administering oxycodone at a dosage which provides a significantly better effect than the orally equipotent dosage of morphine or other opioid, wherein the equipotency refers to the treatment of cutaneous and muscular pain.
  • a method of selectively treating acute visceral pain in a patient comprising orally administering oxycodone in an effective amount to provide analgesia in a patient in need thereof.
  • a method of treating moderate to severe visceral pain in a patient already being treated orally with morphine or a salt thereof comprising:
  • oxycodone or a salt thereof in an amount of less than 50% by weight of the morphine or salt thereof. It may be preferred to orally administer oxycodone or a salt thereof in an amount of less than less than 45% by weight, preferably less than 40% by weight, more preferably less than 35% by weight, even more preferably less than 30% by weight and most preferred 25% by weight of the morphine or salt thereof.
  • the present invention includes the following aspects:
  • a method of treating acute visceral pain by administering oxycodone at a dosage which is lower than the corresponding dosage of morphine required for providing the same therapeutic effect.
  • a method of treating visceral pain by administering oxycodone at a dosage which is lower than the corresponding dosage of morphine required for treating the same visceral pain as efficiently.
  • the weight ratio of the aforementioned dosage of oxycodone to the aforementioned dosage of morphine is preferably less than 1:2, more preferably less than 1:2.5, even more preferably less than 1:3 and most preferably less than 1:4.
  • oxycodone or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating visceral pain.
  • oxycodone or a pharmaceutically acceptable salt thereof wherein oxycodone or a pharmaceutically acceptable salt thereof is used for the manufacture of a medicament for treating acute visceral pain.
  • oxycodone or a pharmaceutically acceptable salt thereof wherein oxycodone or a pharmaceutically acceptable salt thereof is used for the manufacture of a medicament for selectively treating visceral pain.
  • oxycodone or a pharmaceutically acceptable salt thereof wherein the medicament is an oral dosage form containing oxycodone or a pharmaceutically acceptable salt thereof.
  • an oral controlled dosage form for the manufacture of a medicament to control visceral pain in human patients, the oral controlled release dosage form comprising:
  • the term “substantially pH-independent” means that the difference, at any given time, between the amount of oxycodone released at pH 1.2 and the amount released at pH 7.5 (when measured in-vitro using USP Basket Method at 100 rpm in 900 ml aqueous buffer), is 15%, preferably 10% (by weight based on the total amount of oxycodone or salt thereof in the dosage form) or less.
  • a method of treating moderate to severe visceral pain in a patient comprising repeatedly administering 5 mg sustained-release oxycodone twice a day, three-times-a-day, or four-times-a-day.
  • a method of treating moderate to severe visceral pain in a patient comprising repeatedly administering 10 mg sustained release oxycodone once a day.
  • the oxycodone-containing medicament is in the form of a solid oral dosage form like a tablet or capsule.
  • the oxycodone-containing oral dosage form provides immediate release of the oxycodone.
  • the oxycodone-containing oral dosage form provides sustained release of the oxycodone.
  • the oxycodone-containing sustained release dosage form is orally administered on a once daily or twice daily basis.
  • the oxycodone-containing medicament comprises oxycodone in an amount of from about 1 mg to about 50 mg, preferably between 1 and 15 mg, more preferably between 5 and 10 mg and especially of about 5 mg or an equivalent amount of pharmaceutically acceptable salt thereof. If the oxycodone-containing medicament is in the form of a sustained release dosage form to be administered on a once daily or twice daily basis, the amount of oxycodone in some cases may be higher and may be in the range from about 5 mg to about 160 mg, but preferably is not exceeding 40 mg, more preferably is not exceeding 20 mg and most preferably is not exceeding 10 mg.
  • a method of treating moderate to severe visceral pain in a patient comprising:
  • the oxycodone-containing medicament may comprise another active agent, preferably another opioid or nonopioid analgesic agent. Preferred combinations of oxycodone and other active agents are described herein above.
  • the experimental studies referred to below are based on a comparison of different drugs at healthy volunteers by applying experimental pain, since clinical studies provide insufficient information, partly due to the great difference that exists between patients and partly due to the fact that most diseases produce many symptoms other than pain, which affects the assessment of pain-killing efficacy.
  • Experimental pain can be administered under controlled conditions in healthy volunteers so that this bias can be avoided.
  • several experimental stimuli are necessary to simulate the complex clinical situation.
  • For testing the efficacy of different opioids for treating visceral pain a standardized test battery of cutaneous, muscular and visceral stimuli was applied. Blood samples were taken for determination of the opioid concentration in plasma.
  • the purpose of the present study was to compare the efficacy of two different opioids on different experimental pain models, where the pain induced is very similar to clinical pain.
  • the experimental pain induced must therefore activate different peripheral deep/visceral pain pathways in several organs during controlled conditions.
  • the intensity of pain was measured as a result of a well-defined pain stimulus consecutively, but the analgesic effect of orally administered opioid is built up according to the flowchart below:
  • Each of the experiments was carried out on healthy volunteers and includes 24 individuals aged between 18 and 65, male/female ratio 1:1, without any previous chronic or recurrent diseases causing pain.
  • the subjects have also undergone a physical examination and have been screened for any diseases with testing of urine (dipsticks for protein and sugar) and blood tests (haemoglobin, C-reactive protein, platelelets, leukocytes, creatinine, aspartate aminotransferase, alkaline phosphatase, prothrombin time) before they were included in the study.
  • the duration of each of the sub-trials will be maximum 2 hours.
  • the subjects were included three times, with a minimum of one week between each trial.
  • morphine was compared with oxycodone.
  • both drugs have been compared with a placebo.
  • the drug substances were tested by using experimental pain models including cutaneous, intramuscular and visceral pain stimulation in healthy subjects.
  • the trials were conducted according to a block-randomised (three blocks), balanced (opioid sequence) double-blind, placebo-controlled cross-over design with three arms (opioids and placebo) and open therapeutic control. Blinding for patients and those giving treatment was undertaken by pouring the medicine together with grape juice (ensuring blinding of placebo) according to the following pattern.
  • the effect of opioids on mechanical stimuli was studied by stimulating skin and muscle with a pressure algometer (Somedia algometer) and by stimulating the oesophagus with a balloon, where the cross-sectional area can be calculated (impedance planimetry). Sensation for electrical stimulations was studied on the skin and in the muscles of the lower arm (“single and repeated stimuli”). It was ensured in this way that both pure peripheral pain and central mechanisms (“repeated stimuli”) are studied. The effect of thermal stimuli was measured on the skin of the lower arm (Somedic thermotest) and in the osophagus by warm and cold water perfusing the balloon. A stimulus-response curve was produced for all types of stimuli.
  • VAS visual analogue scale
  • Blood samples of 10 ml for assessment of the variation in plasma concentration for the opioids were taken from a peripheral venflon for opioid dosage (blank test) and 30, 45, 60, 90 and 120 minutes after dosage. A total of 240 ml blood is therefore taken over the whole trial (4 weeks).
  • the pain threshold was determined for the various stimuli before the trial and after 30 min (expected initial effect), 60 and 90 minutes (expected maximum effect). Stimuli were produced at different intensities for stimulation in skin, muscles and oesophagus. Data were stored electronically and entered on CRFs.
  • the analgesic effect before and during the trial was determined by 2-sided variance analysis with the factors 1) either placebo versus morphine or morphine versus oxycodone and 2) intensity or pain stimulus and the dependent variable “pain score”.
  • the effect on pain quality was studied by the Danish version of the “McGill Pain Questionnaire” being filled in at maximum pain.
  • the effect on pain threshold after 90 minutes was counted as the primary endpoint.
  • the other data effect on other pain intensities, change in the qualitative descriptive words, change in reported area of pain
  • the plasma measurements were thus to be regarded as secondary endpoints used in the descriptive phase to support the effect on pain data.
US11/814,020 2005-01-18 2006-01-17 Use of Oxycodone for Treating Visceral Pain Abandoned US20080200493A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/814,020 US20080200493A1 (en) 2005-01-18 2006-01-17 Use of Oxycodone for Treating Visceral Pain

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
US11/814,020 US20080200493A1 (en) 2005-01-18 2006-01-17 Use of Oxycodone for Treating Visceral Pain
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/050252 A-371-Of-International WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/515,216 Continuation US9271974B2 (en) 2005-01-18 2014-10-15 Use of oxycodone for treating visceral pain

Publications (1)

Publication Number Publication Date
US20080200493A1 true US20080200493A1 (en) 2008-08-21

Family

ID=35871217

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/814,020 Abandoned US20080200493A1 (en) 2005-01-18 2006-01-17 Use of Oxycodone for Treating Visceral Pain
US14/515,216 Active US9271974B2 (en) 2005-01-18 2014-10-15 Use of oxycodone for treating visceral pain

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/515,216 Active US9271974B2 (en) 2005-01-18 2014-10-15 Use of oxycodone for treating visceral pain

Country Status (32)

Country Link
US (2) US20080200493A1 (zh)
EP (1) EP1838318B1 (zh)
JP (1) JP5049139B2 (zh)
KR (10) KR20200128451A (zh)
CN (1) CN101106996B (zh)
AP (1) AP2249A (zh)
AR (1) AR052880A1 (zh)
AT (2) ATE446092T1 (zh)
AU (1) AU2006207498B2 (zh)
BR (1) BRPI0606247A2 (zh)
CA (1) CA2595043C (zh)
CY (1) CY1109660T1 (zh)
DE (2) DE602006009899D1 (zh)
DK (2) DK1838318T3 (zh)
EA (1) EA013544B1 (zh)
ES (1) ES2333901T3 (zh)
HK (1) HK1107933A1 (zh)
HR (1) HRP20090679T1 (zh)
IL (1) IL184530A (zh)
ME (1) ME01066B (zh)
MX (1) MX2007007207A (zh)
MY (1) MY144471A (zh)
NO (1) NO338968B1 (zh)
NZ (1) NZ555852A (zh)
PL (1) PL1838318T3 (zh)
PT (1) PT1838318E (zh)
RS (1) RS51069B (zh)
SI (1) SI1838318T1 (zh)
TW (1) TWI432196B (zh)
UA (1) UA85471C2 (zh)
WO (1) WO2006077212A1 (zh)
ZA (1) ZA200705231B (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances
US9642809B2 (en) 2007-06-04 2017-05-09 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2008004467A0 (en) 2005-11-14 2008-06-30 Rinat Neurosciene Corp Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
BRPI0907135B8 (pt) 2008-03-04 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
AU2010288194B2 (en) 2009-08-28 2013-08-29 Teva Pharmaceuticals International Gmbh Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
DK2710039T3 (en) 2011-05-20 2019-04-01 Alderbio Holdings Llc ANTI-CGRP COMPOSITIONS AND APPLICATION THEREOF
SG194973A1 (en) 2011-05-20 2013-12-30 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
EP2709662B1 (en) 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2016012188A (es) 2014-03-21 2017-04-27 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
JP6937368B2 (ja) 2016-09-23 2021-09-22 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー 難治性片頭痛の治療方法
KR20210094513A (ko) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 알코올-내성 약물 제형
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5945416A (en) * 1996-03-25 1999-08-31 Eli Lilly And Company Method for treating pain
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5958452A (en) * 1994-11-04 1999-09-28 Euro-Celtique, S.A. Extruded orally administrable opioid formulations
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US6103261A (en) * 1993-07-01 2000-08-15 Purdue Pharma Lp Opioid formulations having extended controlled release
US20040254156A1 (en) * 2003-06-10 2004-12-16 Bertrand Le Bourdonnec Sulfonylamino phenylacetamide derivatives and methods of their use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US6103261A (en) * 1993-07-01 2000-08-15 Purdue Pharma Lp Opioid formulations having extended controlled release
US6143322A (en) * 1993-07-01 2000-11-07 Purdue Pharma L.P. Method of treating humans with opioid formulations having extended controlled release
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5672360A (en) * 1993-11-23 1997-09-30 Purdue Pharma, L.P. Method of treating pain by administering 24 hour oral opioid formulations
US5958452A (en) * 1994-11-04 1999-09-28 Euro-Celtique, S.A. Extruded orally administrable opioid formulations
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5945416A (en) * 1996-03-25 1999-08-31 Eli Lilly And Company Method for treating pain
US20040254156A1 (en) * 2003-06-10 2004-12-16 Bertrand Le Bourdonnec Sulfonylamino phenylacetamide derivatives and methods of their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bjerregaard et al (Anesthesiology Res and Pract 2012:1-5; 2012) *
Riviere (Brit J Pharmcol 141:1331-1334, 2004) *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9642809B2 (en) 2007-06-04 2017-05-09 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9358295B2 (en) 2009-02-06 2016-06-07 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances

Also Published As

Publication number Publication date
CY1109660T1 (el) 2014-08-13
BRPI0606247A2 (pt) 2009-06-09
JP5049139B2 (ja) 2012-10-17
KR20120089710A (ko) 2012-08-13
DK1838318T3 (da) 2010-01-04
JP2008526927A (ja) 2008-07-24
WO2006077212A1 (en) 2006-07-27
EP1838318A1 (en) 2007-10-03
KR20190135557A (ko) 2019-12-06
KR20210131450A (ko) 2021-11-02
TWI432196B (zh) 2014-04-01
KR20200128451A (ko) 2020-11-12
EA200701541A1 (ru) 2008-02-28
CN101106996A (zh) 2008-01-16
CA2595043C (en) 2013-11-19
CN101106996B (zh) 2013-10-23
NO20074174L (no) 2007-10-17
NZ555852A (en) 2010-01-29
KR20230170811A (ko) 2023-12-19
AU2006207498A1 (en) 2006-07-27
KR20220165797A (ko) 2022-12-15
ZA200705231B (en) 2008-06-25
AP2249A (en) 2011-07-18
AT9895U1 (de) 2008-05-15
ES2333901T3 (es) 2010-03-02
RS51069B (sr) 2010-10-31
KR20080106991A (ko) 2008-12-09
AP2007004057A0 (en) 2007-08-31
HK1107933A1 (en) 2008-04-25
UA85471C2 (ru) 2009-01-26
PT1838318E (pt) 2009-12-15
ATE446092T1 (de) 2009-11-15
US9271974B2 (en) 2016-03-01
EP1838318B1 (en) 2009-10-21
US20150190393A1 (en) 2015-07-09
DK200700207U1 (da) 2007-08-24
ME01066B (me) 2012-10-20
AU2006207498B2 (en) 2009-11-19
EA013544B1 (ru) 2010-06-30
MY144471A (en) 2011-09-30
IL184530A (en) 2015-01-29
KR20170021905A (ko) 2017-02-28
NO338968B1 (no) 2016-11-07
MX2007007207A (es) 2007-08-15
DE602006009899D1 (de) 2009-12-03
KR20070100368A (ko) 2007-10-10
DK200700207U3 (da) 2007-09-28
AR052880A1 (es) 2007-04-11
DE202006019887U1 (de) 2007-07-26
CA2595043A1 (en) 2006-07-27
SI1838318T1 (sl) 2010-02-26
IL184530A0 (en) 2007-10-31
TW200637554A (en) 2006-11-01
HRP20090679T1 (hr) 2010-01-31
PL1838318T3 (pl) 2010-03-31
KR20140091782A (ko) 2014-07-22

Similar Documents

Publication Publication Date Title
US9271974B2 (en) Use of oxycodone for treating visceral pain
CN103347495B (zh) 治疗帕金森病的阿片样激动剂与阿片样拮抗剂的组合
KR20070107805A (ko) 옥시코돈 및 날록손 함유 제형
PT2266564E (pt) Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
JP6232135B2 (ja) 疼痛およびオピオイドによる腸機能障害症候群の治療のためのヒドロモルホンおよびナロキソン
NZ763555A (en) Delayed release deferiprone tablets and methods of using the same
AU2017276288A1 (en) Reducing drug liking in a subject

Legal Events

Date Code Title Description
AS Assignment

Owner name: PURDUE PHARMA L.P., CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DREWES, ASBJORN MOHR;NIELSEN, LARS ARENDT;REEL/FRAME:020890/0570;SIGNING DATES FROM 20080404 TO 20080414

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION